Genmab’s revenue for Q1 2026 rose 25% to $896 million, driven by increased royalties from DARZALEX and Kesimpta. Operating costs increased to $716 million, resulting in an operating profit of $180 million. The company maintains its full-year revenue forecast of $4.1-4.4 billion. Net profit for the quarter was $53 million, down from $195 million in Q1 2025. Total assets as of March 31, 2026, were $12,376 million, and shareholders’ equity was $5,682 million. The number of employees rose to 3,088.
Hurtige nyheder er stadig i beta-fasen, og fejl kan derfor forekomme.